



NSGO-CTU

Nordic Society of Gynaecological Oncology - Clinical Trial Unit

Agenda (draft) v.1.49

NSGO-CTU Investigator Meeting

7th – 8th December 2023

Copenhagen, Denmark

Scandic Kødbyen Skelbækgade 3A

1717 Copenhagen V



Wednesday 6. December 2023

13:00-14:15 **NSGO-CTU Foundation Meeting** (Closed meeting)

Meeting Room 10 + 11

14:30-15:45 **NSGO Board Meeting** (Closed meeting)

Meeting Room 10 + 11

16:00-17:30 **NSGO-CTU Scientific Committee Meeting** (Closed meeting)

Meeting Room 10 + 11

18:00-19:00 **Dinner** (Closed Dinner for NSGO BOARD -, NSGO-CTU Foundation -, NSGO-CTU Scientific Committee Members and NSGO-CTU Office Staff)

Restaurant Mør

Thursday 7. December 2023

08:30-09:30 Registration & Exhibition

Foyer & Ballroom 3

09:30-09:50 Welcome by Medical Director

Future plans and status report of NSGO-CTU activities

Ballroom 1 + 2 **Mansoor Raza Mirza**

09:50-09:55 Cervical Cancer

Introduction to the Session

Ballroom 1 + 2 **Chairs: Maria Bjurberg and Kristine Madsen**

09:55-10:50 Cervical Cancer Trials

Ballroom 1 + 2

09:55-10:02 ENGOT-CX11/KEYNOTE-A18

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer

Domenica Lorusso

10:02-10:09 ENGOT-CX10/BEATcc

A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent or Recurrent Carcinoma of the Cervix

Ana Oaknin

10:09-10:16 ENGOT-CX8/GCT1015-05

Randomized, open label, phase 1b/2 first line trial with Tisotumab Vedotin

Kristine Madsen

10:16-10:23 ENGOT-CX12/SGNTV003

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice

Chemotherapy in Second- or Third-Line
Recurrent or Metastatic Cervical Cancer

Maria Bjurberg

10:23-10:30 ENGOT-CX19/eVOLVE

Randomized Phase 2/3 Trial of Volrustomig vs. placebo for patients with FIGO stage IIIC-IVA cervical cancer who have completed, and not progressed, following SOC CCRT (≥ 4 cycles)

Trine Jakobi Nøttrup

10:30-10:37 ENGOT-CX20

MK-2870 in cervical cancer

Kristina Lindemann

10:37-10:50 Discussion

Domenica Lorusso

Ana Oaknin

Trine Jakobi Nøttrup

Kristina Lindemann

10:50-11:15 Break & Exhibition

Ballroom 3

11:15-14:00 NSGO-CTU Scientific Satellite Symposium incl. Lunch

Endometrial Cancer Management in the Era of Immunotherapy

Ballroom 1 + 2

Chairs: Line Bjørge and Henrik Roed

Educational Grant Provided by GSK

**11:20-11:45 50 Years of Management of
Endometrial Cancer**

Jonathan Ledermann

**11:45-12:10 Immunotherapy in Endometrial
Cancer**

Ana Oaknin

**12:10-12:45 Management of Immune-related
Toxicity**

Domenica Lorusso

12:45–13:00 Discussion

Jonathan Ledermann

Ana Oaknin

Domenica Lorusso

13:00–14:00 Symposium Lunch

Restaurant Mør

14:00–14:05 Endometrial Cancer

Introduction to the Session

Ballroom 1 + 2

Chairs: Ane Gerda Zahl Eriksson and Gabriel Lindahl

14:05–15:10 Endometrial Cancer: Neoadjuvant, First - and Second Line Trials incl. Maintenance

Ballroom 1 + 2

14:05–14:12 PELENEO (Neoadjuvant study)

A phase II clinical trial investigating pembrolizumab and lenvatinib in neoadjuvant treatment of advanced endometrial cancer

Kristina Lindemann

14:12–14:19 ENGOT-EN11

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy with or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery with Curative Intent

Trine Lembrecht Jørgensen

14:19–14:26 ENGOT-EN6/RUBY part 1+2

A Phase 3 Randomized Open-Label Study of TSR-042, an anti-PD-1 Mono-clonal Antibody, Versus Investigator's Choice Chemotherapy in Advanced/Recurrent Endometrial Cancer

Gabriel Lindahl

14:26–14:33 ENGOT-EN10/DUO-E

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line

Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer

[Karin Grisan](#)

14:33-14:40 ENGOT-EN15/KEYNOTE-C93

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

[Heini Lassus](#)

14:40-14:47 ENGOT-EN24/DESTINY

[Mansoor Raza Mirza](#)

14:47-14:55 ENGOT-EN21

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with *TP53WT* Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy

[Kristiina Ojamaa](#)

14:55-15:02 ENGOT-EN23 (2nd line)

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy

[Ingvild Vistad](#)

15:02-15:25 Discussion

[Kristina Lindemann](#)

[Trine Lembrecht Jørgensen](#)

[Heini Lassus](#)

[Mansoor Raza Mirza](#)

[Kristiina Ojamaa](#)

[Ingvild Vistad](#)

[Katharina Bischof](#)

[Karin Grisan](#)

15:25-17:00 Break & Exhibition*Ballroom 3***17:00-20:30 NSGO-CTU Scientific Satellite Symposium incl. Dinner**

Novel First Line Therapies in Ovarian Cancer

Ballroom 1 + 2 **Chairs: TBA and Mansoor Raza Mirza****Educational Grant Provided by AstraZeneca****17:00-17:30 Bevacizumab and PARP-inhibitors
in Combination with
Immunotherapy:
Challenges/Missing Information in
Trial Design and Interpretation of
Results****Nicoletta Colombo****17:30-18:00 Current Maintenance Therapy
Approach in First Line Treatment**
Ingrid Boere**18:00-18:30 The Role of Immunotherapy in
Ovarian Cancer**
Philipp Harter**18:30-19:00 Discussion**
Nicoletta Colombo
Ingrid Boere
Philipp Harter**19:00-20:30 Symposium Dinner***Restaurant Mør*

Please evaluate the day by scanning the QR code with your mobile camera and open the link

Friday 8. December 2023

08:00-08:15 Ovarian Cancer: NSGO-CTU-HERO (Observational study)

Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study

Ballroom 1 + 2

Trine Jakobi Nøttrup

08:15-08:20 Ovarian Cancer: Surgical Trials

Introduction to the Session

Ballroom 1 + 2

Chairs: Trine Jakobi Nøttrup and Marta Lomnytska

08:20-08:40 Primary Surgery and HIPEC

Ballroom 1 + 2

08:20-08:27 OVHIPEC-2

Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

Berit Jul Mosgaard

08:27-08:40 Discussion

Berit Jul Mosgaard

Tine Henrichsen-Schnack

08:40-08:45 Ovarian Cancer: First Line Trials

Introduction to the Session

Ballroom 1 + 2

Chairs: Hanna Dahlstrand and Jørn Herrstedt

08:45-09:10 First Line Maintenance Therapy with Bevacizumab/PARP-i

Ballroom 1 + 2

08:45-08:52 ENGOT-OV25/PAOLA-1

Randomised, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Cancer, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining

Platinum-Taxane Chemotherapy and Bevacizumab
Concurrent with Chemotherapy and in Maintenance

[Gabriel Lindahl](#)

08:52-08:59 ENGOT-OV26/PRIMA

A Phase III, Randomized, Double-Blind, Placebo-
Controlled, Multicenter Study of Niraparib
Maintenance Treatment in Patients with Advanced
Ovarian Cancer Following Response on Front-Line
Platinum-Based Chemotherapy

[Nicoline Raaschou-Jensen](#)

08:59-09:10 Discussion

[Gabriel Lindahl](#)

[Nicoline Raaschou-Jensen](#)

[Maarit Anttila](#)

09:10-09:55 Immunotherapy as First Line Treatment

[Hanna Dahlstrand and Jørn Herrstedt](#)

Ballroom 1 + 2

09:10-09:17 ENGOT-OV44/FIRST

An adaptive Randomized Phase III Comparison of
Standard Platinum Based Treatment Versus
Platinum and TSR-042 followed by Niraparib and
TSR-042 maintenance Therapy in Patients with
epithelial Stage III or IV Cancer of the Ovary,
Fallopian Tube, or Peritoneum

[Jørn Herrstedt](#)

09:17-09:24 ENGOT-OV46/DUO-0

Phase III Randomized, Double Blind, Placebo
Controlled, Multicentre Study of durvalumab in
combination with chemotherapy and bevacizumab
followed by maintenance durvalumab, bevacizumab
and olaparib in newly diagnosed advanced ovarian
cancer patients

[Henna Kärkkäinen](#)

09:24-09:33 ENGOT-OV45/ATHENA

A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Phase 3 Study in Ovarian Cancer Patients
Evaluating Rucaparib and Nivolumab as Maintenance
Treatment following Response to Front-Line
Platinum-Based Chemotherapy

Josefin Fernebro

09:33–09:55 Discussion

Henna Kärkkäinen

Josefin Fernebro

09:55–10:30 Break & Exhibition

Ballroom 3

10:30–11:10 Ovarian Cancer: Platinum is an Option & Maintenance

Ballroom 1 + 2

Chairs: Trine Zeeberg Iversen and Birute Brasiuniene

10:30–10:46 ENGOT-OV56/DOVACC

A Randomized Clinical Trial Investigating Olaparib, Durvalumab and UV1 as Maintenance Therapy in BRCAwt Patients with Relapsed Ovarian Cancer

Susanne Malander

10:46–10:53 KANDOVA

A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy and to determine the Recommended Phase II Dose (RPIID). An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Hanna Dahlstrand

10:53–11:10 Discussion

Susanne Malander

Maria Dimoula

Trine Stokstad

11:10–12:00 Ovarian Cancer: Platinum is Not an Option and Palliation

Ballroom 1 + 2

Chairs: Kristina Lindemann and Susanne Malander

11:10–11:17 ENGOT-OV65

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Anne Marie Hansson

11:17-11:24 ENGOT-OV68/ARTISTRY-7

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Birute Brasiuniene

11:24-11:31 ENGOT-OV79/REFRaME-01

Randomized phase 2/3 Study of Luvelta vs. Standard Chemotherapy in Platinum Resistant Ovarian Cancer

Trine Zeeberg Iversen

11:31-11:38 EPIK-0

A Phase III, multi-center, randomized (1:1), openlabel, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer

Annika Auranen

11:38-11:45 PEACE

Palliation in gynae-oncology: Evaluation and Assessment of satisfaction with care

Kristina Lindemann

11:45-12:00 Discussion

Anne Marie Hansson

Birute Brasiuniene

Elisabeth Berge Nilsen

Trine Zeeberg Iversen

Annika Auranen

Ulrika Joneborg

12:00-13:00 Lunch

Restaurant Mør

13:00-13.15 Coffee & Exhibition

Ballroom 3

13:15-15:10 Translational Research Session

Chair(s): [Line Bjørge](#)

Ballroom 1 + 2

(25 + 5 min) The untapped potential of ascites derived ctDNA to direct precision medicine in ovarian cancer

[Caroline Ford](#)

(10 min) Analysis of the impact of germline and somatic alterations, PD-L1 expression and chemotherapy modifications on the outcomes of advanced ovarian cancer patients

[Rasa Malonyté](#)

(25 + 5 min) Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease

[Hilde Eide Lien](#)

TBA TBA

15:10-15:15 Closing Remarks

Chair(s): [Line Bjørge](#)

Ballroom 1 + 2

Please evaluate the day and the meeting in general by scanning the below QR codes with your mobile camera and open the link

This Meeting is Sponsored by

Gold Sponsors:



Exhibitors:

